Az madm-2 (protoonkogén) expresszió klinikai jelentösége hererákokban. Osszefüggés a tumorprogresszióval.

Translated title of the contribution: The clinical value of mdm-2 (proto-oncogene) expression in testicular cancer, Correlation with tumor progression

M. Bak, L. Géczi, E. Institioris, H. Eid, I. Bodrogi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

To determine whether mdm-2 protein level is aberrant in germ cell testicular tumors (GCTT) and if so, what is the relationship between mdm-2 overexpression and other disease parameter including histologic subtypes, p53 status, metastatic potential, and clinical stage, 81 testicular germ-cell tumors were screened for their mdm-2 expression at the protein levels using immunohistochemistry (IHC) and Western blot (WB) analysis. Overall, in this study 45 (55.6%) tumors showed positive mdm-2 nuclear immunoreactivity. The incidence of mdm-2 immunostaining was significantly higher (p = 0.0007) in non-seminomas (NSGCT) than in seminomas (S). The frequency of positive tumor was higher in tumors from metastatic patients than in tumors of patients free from metastasis (p = 0.011). Mdm-2 expression was detected significantly more frequently in tumors of advanced stages, i.e. II/B, II/C, and III versus tumors of early stages (I and II/A) (p = 0.0098). A significant difference could be established between the three stages of disease and the expression of mdm-2 (chi 2 = 0.0386), namely the incidence of mdm-2 expression increased with an advanced stage. Using Western blotting 22 (68.8%) out of 32 tumors overexpressed the mdm-2 oncoprotein of 90 kd (p90). Mdm-2 expression as detected by immunostaining may provide a reliable prognostic tool to subgroup of patients with more aggressive GCTT.

Original languageHungarian
Pages (from-to)1837-1840
Number of pages4
JournalOrvosi Hetilap
Volume140
Issue number33
Publication statusPublished - Aug 15 1999

Fingerprint

Proto-Oncogenes
Testicular Neoplasms
Neoplasms
Proto-Oncogene Proteins c-mdm2
Western Blotting
Seminoma
Oncogene Proteins
Incidence
Immunohistochemistry
Neoplasm Metastasis
Testicular Germ Cell Tumor

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Az madm-2 (protoonkogén) expresszió klinikai jelentösége hererákokban. Osszefüggés a tumorprogresszióval. / Bak, M.; Géczi, L.; Institioris, E.; Eid, H.; Bodrogi, I.

In: Orvosi Hetilap, Vol. 140, No. 33, 15.08.1999, p. 1837-1840.

Research output: Contribution to journalArticle

@article{e279d99ce6214fddab91e9497221816b,
title = "Az madm-2 (protoonkog{\'e}n) expresszi{\'o} klinikai jelent{\"o}s{\'e}ge herer{\'a}kokban. Osszef{\"u}gg{\'e}s a tumorprogresszi{\'o}val.",
abstract = "To determine whether mdm-2 protein level is aberrant in germ cell testicular tumors (GCTT) and if so, what is the relationship between mdm-2 overexpression and other disease parameter including histologic subtypes, p53 status, metastatic potential, and clinical stage, 81 testicular germ-cell tumors were screened for their mdm-2 expression at the protein levels using immunohistochemistry (IHC) and Western blot (WB) analysis. Overall, in this study 45 (55.6{\%}) tumors showed positive mdm-2 nuclear immunoreactivity. The incidence of mdm-2 immunostaining was significantly higher (p = 0.0007) in non-seminomas (NSGCT) than in seminomas (S). The frequency of positive tumor was higher in tumors from metastatic patients than in tumors of patients free from metastasis (p = 0.011). Mdm-2 expression was detected significantly more frequently in tumors of advanced stages, i.e. II/B, II/C, and III versus tumors of early stages (I and II/A) (p = 0.0098). A significant difference could be established between the three stages of disease and the expression of mdm-2 (chi 2 = 0.0386), namely the incidence of mdm-2 expression increased with an advanced stage. Using Western blotting 22 (68.8{\%}) out of 32 tumors overexpressed the mdm-2 oncoprotein of 90 kd (p90). Mdm-2 expression as detected by immunostaining may provide a reliable prognostic tool to subgroup of patients with more aggressive GCTT.",
author = "M. Bak and L. G{\'e}czi and E. Institioris and H. Eid and I. Bodrogi",
year = "1999",
month = "8",
day = "15",
language = "Hungarian",
volume = "140",
pages = "1837--1840",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "33",

}

TY - JOUR

T1 - Az madm-2 (protoonkogén) expresszió klinikai jelentösége hererákokban. Osszefüggés a tumorprogresszióval.

AU - Bak, M.

AU - Géczi, L.

AU - Institioris, E.

AU - Eid, H.

AU - Bodrogi, I.

PY - 1999/8/15

Y1 - 1999/8/15

N2 - To determine whether mdm-2 protein level is aberrant in germ cell testicular tumors (GCTT) and if so, what is the relationship between mdm-2 overexpression and other disease parameter including histologic subtypes, p53 status, metastatic potential, and clinical stage, 81 testicular germ-cell tumors were screened for their mdm-2 expression at the protein levels using immunohistochemistry (IHC) and Western blot (WB) analysis. Overall, in this study 45 (55.6%) tumors showed positive mdm-2 nuclear immunoreactivity. The incidence of mdm-2 immunostaining was significantly higher (p = 0.0007) in non-seminomas (NSGCT) than in seminomas (S). The frequency of positive tumor was higher in tumors from metastatic patients than in tumors of patients free from metastasis (p = 0.011). Mdm-2 expression was detected significantly more frequently in tumors of advanced stages, i.e. II/B, II/C, and III versus tumors of early stages (I and II/A) (p = 0.0098). A significant difference could be established between the three stages of disease and the expression of mdm-2 (chi 2 = 0.0386), namely the incidence of mdm-2 expression increased with an advanced stage. Using Western blotting 22 (68.8%) out of 32 tumors overexpressed the mdm-2 oncoprotein of 90 kd (p90). Mdm-2 expression as detected by immunostaining may provide a reliable prognostic tool to subgroup of patients with more aggressive GCTT.

AB - To determine whether mdm-2 protein level is aberrant in germ cell testicular tumors (GCTT) and if so, what is the relationship between mdm-2 overexpression and other disease parameter including histologic subtypes, p53 status, metastatic potential, and clinical stage, 81 testicular germ-cell tumors were screened for their mdm-2 expression at the protein levels using immunohistochemistry (IHC) and Western blot (WB) analysis. Overall, in this study 45 (55.6%) tumors showed positive mdm-2 nuclear immunoreactivity. The incidence of mdm-2 immunostaining was significantly higher (p = 0.0007) in non-seminomas (NSGCT) than in seminomas (S). The frequency of positive tumor was higher in tumors from metastatic patients than in tumors of patients free from metastasis (p = 0.011). Mdm-2 expression was detected significantly more frequently in tumors of advanced stages, i.e. II/B, II/C, and III versus tumors of early stages (I and II/A) (p = 0.0098). A significant difference could be established between the three stages of disease and the expression of mdm-2 (chi 2 = 0.0386), namely the incidence of mdm-2 expression increased with an advanced stage. Using Western blotting 22 (68.8%) out of 32 tumors overexpressed the mdm-2 oncoprotein of 90 kd (p90). Mdm-2 expression as detected by immunostaining may provide a reliable prognostic tool to subgroup of patients with more aggressive GCTT.

UR - http://www.scopus.com/inward/record.url?scp=0033566476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033566476&partnerID=8YFLogxK

M3 - Article

C2 - 10489783

AN - SCOPUS:0033566476

VL - 140

SP - 1837

EP - 1840

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 33

ER -